CALT Calliditas Therapeutics AB ADRs

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Lead product candidate Nefecon is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, (IgAN) for which there is a high unmet medical need and there are no approved treatments. This is an ADR of a company whose stock trades outside of the U.S. as the symbol SS:CALTX.

$22.41  +0.16 (0.72%)
As of 10/15/2021 10:48:30 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  Sweden
Country of incorporation:  
IPO date:  06/05/2020
Outstanding shares:  26,170,792
Average volume:  15,637
Market cap:   $582,300,122
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.60
PS ratio:   12,570.40
Return on equity:   -61.17%
Net income %:   -148,437.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy